In a significant step toward understanding and combating childhood cancers and congenital disorders, the Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH), has released two comprehensive new datasets. Focusing on childhood
In an unexpected turn of events that sent ripples through the biotechnology sector, Pliant Therapeutics' shares experienced a dramatic plunge after the company voluntarily halted the Phase 2b/3 trial of its experimental fibrosis drug, bexotegrast. The decision, advised by a clinical trial
Recent findings illuminate the potential benefits of BIO 300, an oral suspension aimed at improving lung function in COVID-19 patients following hospital discharge. Results from a Phase 2 clinical trial, conducted by Humanetics Corporation, underscore the drug's ability to significantly
Dengue fever, a mosquito-borne viral disease, affects millions of people worldwide, particularly in tropical and subtropical regions. This debilitating illness is transmitted by infected Aedes mosquitoes, leading to severe symptoms and complications for many afflicted individuals. Despite the high
Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of p
The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is
